SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 1,799 Shares

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 1,799 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $12.95, for a total value of $23,297.05. Following the transaction, the senior vice president owned 284,175 shares of the company’s stock, valued at approximately $3,680,066.25. This trade represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

SiBone Stock Performance

SiBone stock remained flat at $13.12 during midday trading on Friday. 673,231 shares of the company traded hands, compared to its average volume of 599,931. SiBone has a one year low of $12.15 and a one year high of $21.89. The stock has a market capitalization of $579.51 million, a P/E ratio of -29.82 and a beta of 0.77. The stock has a 50-day moving average of $14.69 and a two-hundred day moving average of $16.39. The company has a quick ratio of 7.21, a current ratio of 8.55 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.09. The business had revenue of $56.35 million during the quarter, compared to analyst estimates of $56.26 million. SiBone had a negative net margin of 9.41% and a negative return on equity of 11.01%. As a group, equities research analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SiBone

Several institutional investors have recently bought and sold shares of the stock. First Eagle Investment Management LLC boosted its holdings in shares of SiBone by 36.6% during the 3rd quarter. First Eagle Investment Management LLC now owns 484,261 shares of the company’s stock valued at $7,128,000 after purchasing an additional 129,723 shares during the last quarter. Impax Asset Management Group plc increased its holdings in shares of SiBone by 48.2% in the third quarter. Impax Asset Management Group plc now owns 1,025,010 shares of the company’s stock worth $15,088,000 after purchasing an additional 333,249 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its position in shares of SiBone by 337.7% in the third quarter. Y Intercept Hong Kong Ltd now owns 83,369 shares of the company’s stock worth $1,227,000 after buying an additional 64,322 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of SiBone in the third quarter worth about $3,297,000. Finally, Divisadero Street Capital Management LP boosted its stake in SiBone by 17.8% during the second quarter. Divisadero Street Capital Management LP now owns 339,791 shares of the company’s stock valued at $6,395,000 after buying an additional 51,363 shares during the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on SIBN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research note on Monday, December 29th. Truist Financial reaffirmed a “buy” rating and issued a $24.00 price objective (up from $23.00) on shares of SiBone in a research note on Tuesday, February 24th. TD Cowen increased their target price on SiBone from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Canaccord Genuity Group lifted their target price on SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Wall Street Zen raised SiBone from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.67.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.